Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.23USD
10:15am EST
Change (% chg)

$-0.00 (-0.09%)
Prev Close
$0.23
Open
$0.24
Day's High
$0.24
Day's Low
$0.22
Volume
61,415
Avg. Vol
186,127
52-wk High
$2.13
52-wk Low
$0.22

Summary

Name Age Since Current Position

David Rickey

59 2013 Independent Chairman of the Board

Marc Hedrick

52 2014 President, Chief Executive Officer, Director

Tiago Girao

35 2015 Chief Financial Officer, Chief Accounting Officer, Vice President - Finance

Seijiro Shirahama

60 2007 President , Asia Pacific

John Harris

2015 Vice President, General Manager - Cell Therapy

Jeremy Hayden

2015 Vice President - Business Development, General Counsel

Mark Marino

2016 Chief Medical Officer

Gregg Lapointe

2017 Director

Richard Hawkins

68 2007 Independent Director

Gary Lyons

66 2013 Independent Director

Ronald Martell

54 2016 Independent Director

Gail Naughton

61 2014 Independent Director

Biographies

Name Description

David Rickey

Mr. David M. Rickey is Independent Chairman of the Board of the Company. Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation (AMCC), which provides high-performance, high-bandwidth silicon solutions for optical networks, from February 1996 to March 2005. Mr. Rickey served on the Board of Directors of AMCC from February 1996 to March 2005, and as its Chairman of the Board from August 2000 to March 2005. Mr. Rickey also served as a Director of AMI Semiconductor, Inc. from 2000 to 2006 and was a Director of Netlist, Inc. from 2005 to 2008, as well as several private technology companies. He holds a B.S. from Marietta College, a B.S. from Columbia University and an M.S. from Stanford University.

Marc Hedrick

Dr. Marc H. Hedrick, M.D., is appointed as Chief Executive Officer of the Company in April 2014. He is appointed as President of the Company in May 2004, and joined us as Chief Scientific Officer, Medical Director and Director in October 2002. In December 2000, Dr. Hedrick co-founded and served as President and Chief Executive Officer and Director of StemSource, Inc., a company specializing in stem cell research and development, which was acquired by the Company in 2002. He is a plastic surgeon and is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, he directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick earned his M.D. degree from University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management. Dr. Hedrick’s qualifications to sit on our Board of Directors include his experience as a general, vascular and plastic surgeon; his academic appointments and achievements in the life sciences; his executive and managerial experience in stem cell research and scientific product development, and his foundational knowledge, experience and contributions to the specific technology and operations of our company. In addition, Dr. Hedrick has extensive global experience and familiarity with the cell therapy and regenerative medical industry. On April 2, 2014 the Board of Director’s appointed Dr. Hedrick as Chief Executive Officer.

Tiago Girao

Mr. Tiago Girao is Chief Financial Officer, Chief Accounting Officer, Vice President - Finance of the Company. He was Interim Chief Accounting Officer of Cytori therapeutics Inc. Mr. Girao joined Cytori Therapeutics from NuVasive, Inc. where he recently served as International Controller from February 2014 to August 2014. Prior to his International Controller role, he served as Director, Financial Reporting, where he managed a team responsible for all corporate technical accounting and SEC related matters from March 2012 to February 2014. Prior to joining NuVasive, Mr. Girao served as Senior Manager, Assurance at KPMG, Cytori’s independent audit firm from October 2004 to March 2012. Prior to joining KPMG, Mr. Girao was a senior accountant for Ernst & Young in Brazil from October 2000 to August 2004. Mr. Girao is a certified public accountant with 14 years experience in the accounting, finance and reporting for U.S. and public companies and substantial experience in global finance and operations.

Seijiro Shirahama

Mr. Seijiro N. Shirahama is President, Asia Pacific of Cytori Therapeutics Inc. Mr. Shirahama had served as Senior Vice President – Asia Pacific since November 2006, and as Vice President – Asia Pacific, from September 2002 to November 2006. Prior to that, from May 1999 to August 2002, he was President of Touchmetrics K.K., a diagnostic ultrasound firm. He held executive positions with Bristol-Myers Squibb K.K. from April 1997 to October 1998, and from March 1995 until March 1997, was the General Manager for Baxter Biotech Group in Tokyo, Japan. Mr. Shirahama holds a B.A. from Kanagawa University in Yokohama, Japan and an M.A. from the University of San Francisco.

John Harris

Mr. John D. Harris has been appointed as Vice President and General Manager - Cell Therapy of Cytori Therapeutics, Inc. effective October 1, 2015. Mr. Harris joins Cytori from Becton Dickinson, where he serves as President of Becton Dickinson's Japanese operations, which include a production facility, over 550 employees, and approximately $315 million in revenues. Prior to his current leadership role at Becton Dickinson, Mr. Harris served as the business director of Becton Dickinson's Medical Systems business unit and shortly thereafter also assumed the lead of the Preanalytical Systems business unit. Prior to joining BD, he functioned in key leadership positions with several healthcare and technology-related companies in the U.S., including Tyco Electronics (Asia Medical Sales Director), Delphi Medical Systems (Global Business Development Manager), and Kimberly-Clark/Ballard Medical Products (Senior Business Development Manager). Mr. Harris speaks fluent Japanese and currently resides in Japan with his wife and children. In addition to his various corporate roles, Mr. Harris is a member of the Board of Governors of the American Chamber of Commerce in Japan (ACCJ) and a member of the Executive Committee of the American Medical Device & Diagnostics Association (AMDD), where he chairs the regenerative medicine working group. Mr. Harris holds Master of Business Administration (MBA) and Bachelor of Arts (BA) degrees from University of Utah.

Jeremy Hayden

Mr. Jeremy Bragg Hayden is Vice President - Business Development, General Counsel of Cytori Therapeutics, Inc. Mr. Hayden joins Cytori from Volcano Corporation, where he served as Assistant General Counsel and, among other responsibilities, served as legal business partner to Volcano's business units and supported Volcano's SEC and M&A activities, including Volcano's merger with Royal Philips. Prior to his tenure at Volcano, Mr. Hayden was counsel at several legal firms, including McKenna Long & Aldridge, LLP and Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., during which he advised public and private clients on a broad variety of transactions, including strategic growth, equity and debt investments and acquisitions. Mr. Hayden earned his J.D. from the University of Michigan Law School and an A.B. in politics from Princeton University.

Mark Marino

Gregg Lapointe

Richard Hawkins

Mr. Richard J. Hawkins is an Independent Director of Cytori Therapeutics Inc. In 1982 .In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization (CRO) that merged with the predecessor of PPD-Pharmaco in 1991 and is one of the largest CROs in the world today. In 1992, Mr. Hawkins co-founded Sensus Drug Development, which developed and received regulatory approval for SOMAVERT®, a growth hormone antagonist approved for the treatment of acromegaly, which is now marketed by Pfizer in both the United States and Europe, and he served as Chairman until 2000. In 1994, Mr. Hawkins co-founded Corning Biopro, a contract protein manufacturing firm where he served on the Board until 2000. In September 2003 Mr. Hawkins founded LabNow, Inc., a privately held company that develops lab-on-a-chip sensor technology, where he served as the Chairman and CEO until October 2009. Mr. Hawkins has served on the Board of SciClone Pharmaceuticals, Inc. since October 2004. In February 2011, Mr. Hawkins became CEO, and is currently CEO, of Lumos Pharma, Inc., a start-up pharma company. He served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas in Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University. Mr. Hawkins’s qualifications to sit on our Board of Directors include his executive experience working with life sciences companies, his extensive experience in pharmaceutical research and development, his knowledge, understanding and experience in the regulatory development and approval process and his service on other public company boards and committees.

Gary Lyons

Mr. Gary A. Lyons is Independent Director of the Comapny. Mr. Lyons has served on the Board of Directors of Neurocrine Biosciences since 1993 and as the President and Chief Executive Officer of Neurocrine from 1993 through January 2008. Prior to joining Neurocrine Biosciences, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Inc., Vical Incorporated, and KaloBios Pharmaceuticals, Inc. Mr. Lyons was previously a director of PDL BioPharma, Inc., Poniard Pharmaceuticals, Inc., Neurogesx and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.

Ronald Martell

Mr. Ronald A. Martell serves as Independent Director of the Company. Mr. Martell has more than 25 years' experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals. Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems' worldwide commercial operations and field sales force to market and commercialize Erbitux® with partners Bristol-Myers Squibb and Merck KGaA. Prior to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company's oncology franchise including the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin's lymphoma.

Gail Naughton

Dr. Gail K. Naughton, Ph.D., is Independent Director of the Company. Dr. Naughton was the co-founder and co-inventor of the technology at Advanced Tissue Sciences where she held key management positions for more than 15 years, including President, Chief Operating Officer and Director. She also served as the Dean of the College of Business Administration at San Diego State University for nine years. Currently Dr. Naughton serves as the Chief Executive Officer and the Chairman of the Board of Histogen, a regenerative medicine company she founded in 2007. Dr. Naughton has also served on the Board of Directors for CR Bard, Inc. since 2005. Dr. Naughton holds a B.S. in biology from St. Francis College as well as a Master’s in histology and a Ph.D. in cell biology from New York University Medical Center. She also holds an EMBA from the Anderson School at the University of California, Los Angeles. Dr. Naughton’s qualifications to sit on our Board of Directors include her executive experience working with life sciences companies, her extensive experience in pharmaceutical research and development, her knowledge, understanding and experience in the field of regenerative medicine and her service on other public company boards and committees.